Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Improving antidepressant treatment in the postpartum by manipulating immune signalling: impact on dam and offspring

EF 2021-22

Résumé
During periods of hormone shifts such as the postpartum period, females experience a heightened risk for depression. Antidepressants such as selective serotonin reuptake inhibitors (SSRIS) are beneficial in improving depression symptoms. However, these benefits are rarely seen in women experiencing Postpartum depression (PPD). Children of mothers with PPD show an increased risk of psychiatric disorders. Thus, there is an urgent need to develop better therapies to treat PPD. Current research suggests that this increased risk may be related to inflammatory markers which may also be implicated in antidepressant efficacy. Specifically, the major immune cells in the brain, microglia secrete immune signalling factors called cytokines, such as Interleukin (IL)-1b. IL-1b and microglia are implicated in PPD, SSRI efficacy, and are highly expressed in the hippocampus during depression. Reduced neuroplasticity in the hippocampus is seen in PPD, and IL-1b suppresses hippocampal neuroplasticity. To determine the involvement of IL-1b and microglia in SSRI efficacy in PPD we will administer a drug that reduces the effects of IL-1b along with SSRI treatment in a rodent model of PPD, and measure depressive-like symptoms. We will examine the effects maternal treatments in male and female offspring, particularly stress resilience during adolescence, as this is the time when disorders in children of PPD mothers often emerge. We hypothesize that blocking IL-1b will boost SSRI efficacy and alleviate depressive-like symptoms in the dam and stress resilience in offspring. This project will study the mechanism underlying decreased antidepressant efficacy seen in PPD and may promote viable targets to be used for treatment of PPD, that will benefit the health of both mother and child alike.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
466632
Name
Garcia de leon Montano Romina
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Improving antidepressant treatment in the postpartum by manipulating immune signalling: impact on dam and offspring
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antidepressent Efficacy; Cytokines; Epigenetics; Hippocampus; Microglia; Neurogenesis; Neuroinflammation; Neuroplasticity; Postpartum Depression (Ppd); Stress
Abstract
During periods of hormone shifts such as the postpartum period, females experience a heightened risk for depression. Antidepressants such as selective serotonin reuptake inhibitors (SSRIS) are beneficial in improving depression symptoms. However, these benefits are rarely seen in women experiencing Postpartum depression (PPD). Children of mothers with PPD show an increased risk of psychiatric disorders. Thus, there is an urgent need to develop better therapies to treat PPD. Current research suggests that this increased risk may be related to inflammatory markers which may also be implicated in antidepressant efficacy. Specifically, the major immune cells in the brain, microglia secrete immune signalling factors called cytokines, such as Interleukin (IL)-1b. IL-1b and microglia are implicated in PPD, SSRI efficacy, and are highly expressed in the hippocampus during depression. Reduced neuroplasticity in the hippocampus is seen in PPD, and IL-1b suppresses hippocampal neuroplasticity. To determine the involvement of IL-1b and microglia in SSRI efficacy in PPD we will administer a drug that reduces the effects of IL-1b along with SSRI treatment in a rodent model of PPD, and measure depressive-like symptoms. We will examine the effects maternal treatments in male and female offspring, particularly stress resilience during adolescence, as this is the time when disorders in children of PPD mothers often emerge. We hypothesize that blocking IL-1b will boost SSRI efficacy and alleviate depressive-like symptoms in the dam and stress resilience in offspring. This project will study the mechanism underlying decreased antidepressant efficacy seen in PPD and may promote viable targets to be used for treatment of PPD, that will benefit the health of both mother and child alike.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Garcia de leon Montano, Romina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~